MERRIMACK PHARMACEUTICALS INC Quarterly Nonoperating Income (Expense) in USD from Q1 2017 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Merrimack Pharmaceuticals Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2017 to Q1 2024.
  • Merrimack Pharmaceuticals Inc Nonoperating Income (Expense) for the quarter ending March 31, 2024 was $233K, a 32.4% increase year-over-year.
  • Merrimack Pharmaceuticals Inc Nonoperating Income (Expense) for the twelve months ending March 31, 2024 was $925K.
  • Merrimack Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2023 was $868K, a 362% increase from 2022.
  • Merrimack Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2022 was $188K, a 840% increase from 2021.
  • Merrimack Pharmaceuticals Inc annual Nonoperating Income (Expense) for 2021 was $20K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $925K $233K +$57K +32.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $868K $262K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $252K +$190K +306% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $178K +$170K +2125% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $176K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q3 2022 $62K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $8K -$11K -57.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q2 2021 $19K -$2K -9.52% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q4 2020 -$141K -$208K -$272K -425% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-09
Q3 2020 $131K $1K -$140K -99.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $271K $21K +$193K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $78K $45K +$459K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$381K $64K +$1.56M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-10
Q3 2019 -$1.95M $141K +$544K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$2.49M -$172K +$406K +70.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$2.9M -$414K -$8K -1.97% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$2.89M -$1.5M +$3.34M +69% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$6.23M -$403K -$9.91M -104% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $3.68M -$578K +$24.8M +97.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-17
Q1 2018 -$21.1M -$406K +$1.56M +79.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q4 2017 -$22.6M -$4.84M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 $9.51M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$25.3M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$1.97M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.